[HTML][HTML] Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses

DM Morens, JK Taubenberger, AS Fauci - Cell host & microbe, 2023 - cell.com
Viruses that replicate in the human respiratory mucosa without infecting systemically,
including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other" …

Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy

Q Zhang, R **ang, S Huo, Y Zhou, S Jiang… - Signal transduction and …, 2021 - nature.com
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …

Antiviral approaches against influenza virus

R Kumari, SD Sharma, A Kumar, Z Ende… - Clinical microbiology …, 2023 - journals.asm.org
Preventing and controlling influenza virus infection remains a global public health
challenge, as it causes seasonal epidemics to unexpected pandemics. These infections are …

[HTML][HTML] Deployment of convalescent plasma for the prevention and treatment of COVID-19

EM Bloch, S Shoham, A Casadevall, BS Sachais… - The Journal of clinical …, 2020 - jci.org
Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the cause of coronavirus
disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven …

Convalescent plasma as a potential therapy for COVID-19

L Chen, J **ong, L Bao, Y Shi - The Lancet infectious diseases, 2020 - thelancet.com
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which
originated in Wuhan, China, has become a major concern all over the world. The …

Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update

W Alhazzani, L Evans, F Alshamsi, MH Møller… - Critical care …, 2021 - journals.lww.com
BACKGROUND: The coronavirus disease 2019 pandemic continues to affect millions
worldwide. Given the rapidly growing evidence base, we implemented a living guideline …

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

W Alhazzani, MH Møller, YM Arabi, M Loeb… - Intensive care …, 2020 - Springer
Background The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting …

An update on current therapeutic drugs treating COVID-19

R Wu, L Wang, HCD Kuo, A Shannar, R Peter… - Current pharmacology …, 2020 - Springer
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented …

A randomized trial of convalescent plasma in Covid-19 severe pneumonia

VA Simonovich, LD Burgos Pratx… - … England Journal of …, 2021 - Mass Medical Soc
Background Convalescent plasma is frequently administered to patients with Covid-19 and
has been reported, largely on the basis of observational data, to improve clinical outcomes …

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

MJ Joyner, KA Bruno, SA Klassen, KL Kunze… - Mayo Clinic …, 2020 - Elsevier
Objective To provide an update on key safety metrics after transfusion of convalescent
plasma in hospitalized coronavirus 2019 (COVID-19) patients, having previously …